They talk about us


September 1st, TORMONT50 : MedX Health Report

MedX Health Corp., a speculative micro-cap stock with a current equity valuation of just $12 million, has developed its SIAscopeTM, a Class 2 medical scanning device which, used in conjunction with an HD camera, can scan suspicious – potentially cancerous – moles and lesions and penetrate two millimeters (mm) below the surface of the skin to accurately generate high quality images. See Figure 1 and 2. These images are then uploaded to MedX’s proprietary DermSecureTM telemedicine platform to be securely transmitted to dermatologists for assessment


Press release

May 10, MedX Announces Appointment of Stephen Lockyer as CEO

Stephen, who became a major investor in the company in recent months, and who joined the Board in April, 2023, brings extensive knowledge and years of financial management and entrepreneurial experience, and was instrumental in the introduction of the project with PharmaChoice which has just been launched in Canada,” said Ken McKay, Chairman of the MedX Board of Directors….


April 18, MedX Health and PharmaChoice Announce Agreement to Launch MedX Teledermatology Screening Platform Across Canada

MedX Health Corp. (“MedX” or the “Company“) (TSXV: MDX), a global leader in teledermatology, is pleased to announce a Memorandum of Understanding for the launch of a new commercialization pilot project (the “Pilot Project”) with PharmaChoice Canada (“PharmaChoice”), one of Canada’s fastest‐growing pharmacy groups

More Releases
Get In Touch

Notre impact grandit chaque jour et notre portée est mondiale.

Si vous avez besoin de plus d'informations sur nos services ou notre vision d'entreprise, veuillez nous contacter et nous vous mettrons en relation avec le membre approprié de notre équipe qui pourra mieux vous servir !

1495 Bonhill Road, Unit # 1 Mississauga, ON Canada L5T 1M2
+1 888 363 3112